Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma - PubMed (original) (raw)

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma

R J Motzer et al. J Clin Oncol. 2000 May.

Abstract

Purpose: To evaluate the relationship between treatment with cytokine therapy and survival, investigate the effect of nephrectomy on survival, and identify long-term survivors among a cohort of 670 patients with advanced renal cell carcinoma (RCC).

Patients and methods: A total of 670 patients with advanced RCC treated on 24 clinical trials of systemic chemotherapy or cytokine therapy were the subjects of this retrospective analysis. Treatment was categorized as cytokine (containing interferon alfa and/or interleukin-2) in 396 patients (59%) and as chemotherapy (cytotoxic or hormonal therapy) in 274 (41%). Among the 670 patients, those with survival times of greater than 5 years were identified as long-term survivors.

Results: Patients treated with cytokine therapy had a longer survival time than did those treated with chemotherapy, regardless of the year of treatment or risk category based on pretreatment features. The median survival times for favorable-, intermediate-, and poor-risk patients were 27, 12, and 6 months for those treated with cytokines and 15, 7, and 3 months for those treated with chemotherapy, respectively. The magnitude of difference in median survival was greater in the favorable- and intermediate-risk groups. The median survival time was less than 6 months in the poor-risk group for both treatment programs. Median survival time was 14 months among patients with prior nephrectomy plus time from diagnosis to treatment greater than 1 year versus 8 months among those with time from diagnosis to treatment less than 1 year, regardless of pretreatment nephrectomy status. Thirty patients (4.5%) among the 670 patients were identified as long-term survivors; 12 were free of disease after nephrectomy and treatment with interferon alfa, interleukin-2, or surgical resection of metastasis.

Conclusion: The low proportion of patients with advanced RCC who achieve long-term survival emphasizes the need for clinical investigation to identify more effective therapy.

PubMed Disclaimer

Cited by

Renal cell carcinoma: diagnosis and treatment, 1994-2003.
Hutson TE. Hutson TE. Proc (Bayl Univ Med Cent). 2005 Oct;18(4):337-40. doi: 10.1080/08998280.2005.11928093. Proc (Bayl Univ Med Cent). 2005. PMID: 16252025 Free PMC article. No abstract available.
Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.
Escudier B, Albiges L. Escudier B, et al. Drugs. 2011 Jun 18;71(9):1179-91. doi: 10.2165/11591410-000000000-00000. Drugs. 2011. PMID: 21711062 Review.
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
Kurabayashi A, Inoue K, Fukuhara H, Karashima T, Fukata S, Kawada C, Shuin T, Furihata M. Kurabayashi A, et al. Cancer Sci. 2015 Aug;106(8):1092-9. doi: 10.1111/cas.12711. Epub 2015 Jul 14. Cancer Sci. 2015. PMID: 26041278 Free PMC article.
Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ, Lee YH, Koo KC. Kim TJ, et al. Investig Clin Urol. 2022 Sep;63(5):486-498. doi: 10.4111/icu.20220103. Investig Clin Urol. 2022. PMID: 36067994 Free PMC article. Review.
The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?
Panebianco M, Ciccarese C, Strusi A, Beccia V, Carbone C, Agostini A, Piro G, Tortora G, Iacovelli R. Panebianco M, et al. Cancers (Basel). 2024 Jan 23;16(3):490. doi: 10.3390/cancers16030490. Cancers (Basel). 2024. PMID: 38339243 Free PMC article. Review.

Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma - PubMed (original) (raw)